Effect of Efgartigimod on Humoral Vaccine Responses in Patients with Autoimmune Diseases

The study explores the impact of Efgartigimod, a Neonatal Fc Receptor blocker, on humoral vaccine responses in patients with autoimmune diseases. It discusses how immunosuppressive therapies used in autoimmune disorders may affect susceptibility to infections and impair vaccine immunogenicity, highl

0 views • 18 slides